BG99149A - Нови хиназолини-инхибитори на нiv реверсивна транскриптаза - Google Patents

Нови хиназолини-инхибитори на нiv реверсивна транскриптаза

Info

Publication number
BG99149A
BG99149A BG99149A BG9914994A BG99149A BG 99149 A BG99149 A BG 99149A BG 99149 A BG99149 A BG 99149A BG 9914994 A BG9914994 A BG 9914994A BG 99149 A BG99149 A BG 99149A
Authority
BG
Bulgaria
Prior art keywords
treatment
reserve
inhibitors
niv
prevention
Prior art date
Application number
BG99149A
Other languages
English (en)
Inventor
Terry Lyle
Thomas Tucker
Catherine Wiscount
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG99149A publication Critical patent/BG99149A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до съединения, които иматхиназолин-2-он-ядро, заместено на 4-позиция с алкинил или алкенил. Те намират приложение за инхибиране на нiv обратната транскриптаза, включително нанейните резистентни варианти, за предотвратяване или за лечение на инфекции, предизвикани от нiv, и за лечение на спин, под формата на съединения или на фармацевтично приемливи соли, или на съставки за фармацевтични състави самостоятелно и в комбинация с други антивирусни средства, имуностимулатори,антибиотици или ваксини. Изобретението се отнася също до методи за лечение на спин и за предотвратяване или лечение на предизвиквани от нiv инфекции.
BG99149A 1992-05-07 1994-10-31 Нови хиназолини-инхибитори на нiv реверсивна транскриптаза BG99149A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88011992A 1992-05-07 1992-05-07
US99116492A 1992-12-16 1992-12-16
PCT/US1993/003975 WO1993022292A1 (en) 1992-05-07 1993-04-28 New quinazolines as inhibitors of hiv reverse transcriptase

Publications (1)

Publication Number Publication Date
BG99149A true BG99149A (bg) 1995-06-30

Family

ID=27128564

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99149A BG99149A (bg) 1992-05-07 1994-10-31 Нови хиназолини-инхибитори на нiv реверсивна транскриптаза

Country Status (15)

Country Link
EP (2) EP0639184A1 (bg)
JP (1) JPH0813805B2 (bg)
KR (1) KR950701322A (bg)
CN (1) CN1085550A (bg)
AU (2) AU4220493A (bg)
BG (1) BG99149A (bg)
CA (1) CA2095194A1 (bg)
CZ (1) CZ272494A3 (bg)
FI (1) FI945199A (bg)
HR (1) HRP930857A2 (bg)
HU (1) HUT71401A (bg)
IL (1) IL105551A0 (bg)
MX (1) MX9302681A (bg)
SI (1) SI9300244A (bg)
WO (1) WO1993022292A1 (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone
HRP980143A2 (en) * 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
AU4719799A (en) * 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
EP1183242A2 (en) 1999-05-26 2002-03-06 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
CN1366518A (zh) * 2000-04-25 2002-08-28 三星电子株式会社 作为基质金属蛋白酶抑制剂的联苯基丁酸衍生物
US7119111B2 (en) * 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
WO2009044788A1 (ja) * 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. ベンゾオキサジノン誘導体
CN101544630B (zh) * 2009-05-13 2013-03-13 中国科学院广州生物医药与健康研究院 羟基化茚地那韦的制备方法
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL147140B (nl) * 1968-11-26 1975-09-15 Farmaceutici Italia Werkwijze voor het bereiden van geneesmiddelen met een remmende werking op het centrale zenuwstelsel.
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CN1085550A (zh) 1994-04-20
AU4220493A (en) 1993-11-29
EP0569083A1 (en) 1993-11-10
MX9302681A (es) 1994-05-31
WO1993022292A1 (en) 1993-11-11
HUT71401A (en) 1995-11-28
KR950701322A (ko) 1995-03-23
AU3841393A (en) 1993-11-11
SI9300244A (sl) 1993-12-31
FI945199A0 (fi) 1994-11-04
JPH0813805B2 (ja) 1996-02-14
IL105551A0 (en) 1993-08-18
JPH069578A (ja) 1994-01-18
EP0639184A1 (en) 1995-02-22
CZ272494A3 (en) 1995-10-18
HRP930857A2 (en) 1995-06-30
FI945199A (fi) 1994-11-04
CA2095194A1 (en) 1993-11-08

Similar Documents

Publication Publication Date Title
MXPA03005464A (es) Agentes antivirales.
BG99149A (bg) Нови хиназолини-инхибитори на нiv реверсивна транскриптаза
MX9204720A (es) Derivados de quinazolina como inhibidores de transcriptasa inversa de vih.
DK1441734T3 (da) Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
EA200300449A1 (ru) Аза- и полиаза-нафталинилкарбоксамиды, полезные в качестве ингибиторов вич-интегразы
MY109834A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
IS2436B (is) N-setnir hýdroxýpýrimídínón karboxamíð hindrar afHIV integrasa
HUP0004412A2 (hu) Heterociklikus vinil-éterek alkalmazása neurológiai rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
ATE215952T1 (de) Hiv-proteaseinhibitoren
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
CA2141056A1 (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
PA8471901A1 (es) Derivados de 2"-desoxi higromicina
ATE232727T1 (de) Kombinationen von hiv-protease inhibitoren
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
ECSP961660A (es) Terapia combinada para infeccion por vih